Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Keverprazan hydrochloride - Jiangsu Carephar pharmaceuticals

Next Previous
Drug Profile

Keverprazan hydrochloride - Jiangsu Carephar pharmaceuticals

Alternative Names: Bei Wen; Carenoprazan hydrochloride - Jiangsu Carephar Pharmaceutical; H-008; KFP-H008

Latest Information Update: 10 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Carephar Pharmaceutical
  • Class Anti-inflammatories; Antiulcers; Gastric antisecretories; Small molecules
  • Mechanism of Action Potassium-competitive acid blockers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Duodenal ulcer; Gastro-oesophageal reflux
  • No development reported Erosive oesophagitis

Most Recent Events

  • 09 Jan 2025 Sixth Affiliated Hospital, Sun Yat-sen University plans the phase III KHDT-SGT trial for Helicobacter pylori infections (Treatment-experienced, Combination therapy) (NCT06760065)
  • 28 Jul 2024 No recent reports of development identified for phase-I development in Erosive-oesophagitis(In volunteers) in USA (PO, Tablet)
  • 08 Mar 2023 Efficacy and adverse events data from a phase III trial in Gastro-oesophageal-reflux released by Jiangsu Carephar Pharmaceutical

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top